- ADC Therapeutics: 'Strong Buy' With 2 Shots On Goal For ZYNLONTA In R/R DLBCL
May 5, 2026 · seekingalpha.com
ADC Therapeutics SA remains a Strong Buy, driven by pivotal ZYNLONTA combination trials targeting 2nd-line r/r DLBCL. Topline data from the phase 3 LOTIS-5 trial (ZYNLONTA + rituximab) is expected in Q2 2026, representing a major inflection point. ZYNLONTA + glofitamab in phase 1b LOTIS-7 achieved an 89.8% ORR and 77.6% CR rate, with further data expected by the end of 2026.
- ADC Therapeutics S.A. Q1 2026 Earnings Call Summary
May 4, 2026
ADC Therapeutics S.A. Q1 2026 Earnings Call Summary - Moby
Strategic Performance and Market Positioning
Management attributes the 15% year-over-year revenue growth primarily to normal customer ordering variability rather than a fundamental shift in market demand, which remains broadly stable. ZYNLONTA is positioned as a differentiated treatment for third-line plus DLBCL, characterized by rapid and durable efficacy with a manageable safety profile and convenient administration. The company is executing a life cycle management strategy to expand ZYNLONTA into earlier lines of therapy and indolent lymphomas, targeting peak U.S. annual revenues of $600 million to $1 billion. Operational efficiency improved through a 13% reduction in non-GAAP operating expenses, driven by lower R&D spending and disciplined capital allocation. Management believes the stability of product revenues over multiple quarters validates ZYNLONTA's established role in a highly competitive market environment. Strategic focus is shifting from research and development toward commercial manufacturing activities, reflected in the reallocation of certain personnel costs.
Clinical Catalysts and Growth Trajectory
Top-line data for the LOTIS-5 Phase III confirmatory trial is expected before the end of June 2026, which serves as the primary near-term value catalyst. Management anticipates an accelerated revenue growth trajectory starting in 2027, contingent upon positive clinical readouts and subsequent regulatory approvals. The company expects to submit a supplemental Biologics License Application (sBLA) for LOTIS-5 by year-end 2026, with potential compendia inclusion in the first half of 2027. Full data from the LOTIS-7 trial and various investigator-initiated trials in indolent lymphomas are anticipated between late 2026 and mid-2027. The current cash balance of $231 million is projected to support operations at least into 2028, providing a stable runway to reach upcoming clinical milestones.
Operational Adjustments and Risk Factors
Cost of product sales increased due to a strategic shift in personnel allocation from R&D to commercial manufacturing, a trend expected to continue in future quarters. The company has entered a 'blackout period' regarding LOTIS-5 data, resulting in the cancellation of certain investor and analyst engagements until top-line results are disclosed. Future revenue projections for ZYNLONTA assume both successful regulatory approval and favorable compendia listing for new indications. Management noted that while recent revenue was strong, it is too early to call a definitive change in the long-term sales trend due to historical variability.
Story Continues
Q&A Session Highlights
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
Status of LOTIS-5 unblinding and database lock
Management confirmed they remain completely blinded to the data and did not specify if the 262-event threshold has been reached. The company is on track to lock the database, perform statistical analysis, and share top-line results within the second quarter of 2026.
Scope of data disclosure for upcoming LOTIS-5 readout
The top-line announcement will include primary endpoints such as median PFS and hazard ratios, along with key secondary endpoints and safety data. More granular sub-analyses will be reserved for medical conferences and formal publications later in the year.
Commercial impact and timing of new clinical data
No immediate revenue impact is expected in 2026 following the LOTIS-5 readout; promotion will only begin after formal approval, likely in mid-2027. Compendia inclusion for LOTIS-5 is targeted for the first half of 2027, which typically precedes full regulatory approval.
One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.
View Comments
- ADC Therapeutics targets $600M-$1B U.S. peak ZYNLONTA revenue as LOTIS-5 top-line data is expected by end of June
May 4, 2026
Earnings Call Insights: ADC Therapeutics (ADCT) Q1 2026
MANAGEMENT VIEW
*
"We continue to make good progress in the first quarter of 2026 as we advance towards multiple important milestones for ZYNLONTA over the remainder of the year, beginning with the expected LOTIS-5 top line readout in the second quarter" (CEO & Director Ameet Mallik).
*
"First quarter net product revenues were $20.0 million as compared to the prior year's first quarter net product revenues of $17.4 million" (CEO & Director Mallik), adding that "the increase was driven primarily by normal quarter-to-quarter variability in customer ordering with underlying demand broadly stable" (CEO & Director Mallik).
*
"We expect to share top line data before the end of June" for LOTIS-5, while noting, "we are currently still blinded to the data" (CEO & Director Mallik).
*
"We continue to pay close attention in the quarter to managing our cost base and optimizing our balance sheet" (CEO & Director Mallik), and "we ended the first quarter of 2026 with a healthy cash balance of $231 million" (CEO & Director Mallik).
*
"We are confident that ZYNLONTA has the potential to reach peak annual revenues of $600 million to $1 billion in the U.S., assuming both compendia listing and regulatory approval" (CEO & Director Mallik), and "we expect to accelerate our revenue growth trajectory starting in 2027" (CEO & Director Mallik).
*
"On a GAAP basis, we reported a net loss of $33 million for the first quarter of 2026 or $0.21 per basic and diluted share" (Chief Financial Officer Jose Carmona), and "at the end of the first quarter, we had cash and cash equivalents of $231 million" (Chief Financial Officer Carmona).
OUTLOOK
*
"We expect to share the top line data for LOTIS-5 before the end of June" (Chief Financial Officer Jose Carmona), and "assuming the results are positive, we plan to submit a supplemental biologics license application to the FDA by year-end" (Chief Financial Officer Carmona).
*
"With potential publication and compendia inclusion in the first half of 2027 and confirmatory approval to follow thereafter" (Chief Financial Officer Carmona).
*
"With LOTIS-7, we are on track to complete enrollment in the second quarter" (Chief Financial Officer Carmona), and "we plan to share the next update with full data at a medical meeting by the end of 2026" (Chief Financial Officer Carmona).
*
Compared with the prior quarter’s call, management maintained the LOTIS-5 timing in Q2 2026, while the current call added procedural constraints around communications: "Until the top line data has been presented, we will remain in a blackout period, which means we may need to cancel our participation in any conferences as well as meetings with investors and analysts" (Chief Financial Officer Carmona).
FINANCIAL RESULTS
*
"ZYNLONTA net product revenues in the first quarter of 2026 were $20 million" (Chief Financial Officer Jose Carmona).
*
"Cost of product sales increased by $1.6 million to $3.6 million" (Chief Financial Officer Carmona), and "this increase reflects a shift in the allocation of certain personnel costs due to a change in focus from research and development activities to commercial manufacturing activities" (Chief Financial Officer Carmona).
*
"Total operating expenses were $46.1 million" (Chief Financial Officer Carmona), and "on a non-GAAP basis, total adjusted operating expenses were $42.9 million" (Chief Financial Officer Carmona).
*
"On a non-GAAP basis, the adjusted net loss was $19.7 million for the first quarter of 2026" (Chief Financial Officer Carmona).
*
"At the end of the first quarter, we had cash and cash equivalents of $231 million as compared to $261.3 million as of December 31, 2025" (Chief Financial Officer Carmona).
Q&A
*
Maurice Raycroft, Jefferies: "Can you clarify if the database is locked at this point and when you reach the 262 events?" CEO & Director Mallik: "as soon as the database gets locked and we do the statistical analysis, we'll then be able to disclose top line data... we are on track to basically to share the data this quarter."
*
Maurice Raycroft, Jefferies: "do you have any perspective potentially from the IDMC" on censoring/dropout? CEO & Director Mallik: "I can't comment further... the last IDMC look, which is from a safety standpoint, was last fall... that recommendation wants to proceed as it is."
*
Michael Schmidt, Guggenheim: on commercial upside and the $20M quarter, "curious if there's anything else going on"; CEO & Director Mallik: "it's too soon to call a change in trend" and "we're happy that we've been able to maintain our share despite a very competitive environment."
*
Michael Schmidt, Guggenheim: what will be in LOTIS-5 top-line? CEO & Director Mallik: "we plan to share... the median PFS, hazard ratio... key secondary endpoints as well as top line safety data" while "a lot of sub analyses... would come later in the year."
*
Eric Schmidt, Cantor: "you're now entering the quiet period?" CEO & Director Mallik: "we haven't been engaging with analyst or investors since April 1."
*
Eric Schmidt, Cantor: will LOTIS-5 include OS information? CEO & Director Mallik: "we will give the information that we have on overall survival... I can't comment right now on how many events we have."
*
Eric Schmidt, Cantor: COGS allocation impact? Chief Financial Officer Carmona: "It is going to continue throughout all quarters from now on... the cost of goods are going to increase because of this fixed cost."
*
Sudan Loganathan, Stephens: immediate impact after positive LOTIS-5? CEO & Director Mallik: "we don't expect any revenue impact this year... and only see revenue trajectory increase next year" and "we'll only start promoting the product once we have a formal approval sometime around the middle of next year."
*
Sudan Loganathan, Stephens: value of indolent lymphoma IITs? CEO & Director Mallik: "the data on the full study will be disclosed sometime between the end of this year and the middle of next year" and "publications... and then... submitted for compendia inclusion after that."
SENTIMENT ANALYSIS
*
Analysts were slightly negative to neutral in tone, pressing on timing/process and what could (or could not) be disclosed, including "when you reach the 262 events" (Maurice Raycroft, Jefferies) and whether a sales uptick reflected "more growth than we've seen in recent quarters" (Michael Schmidt, Guggenheim).
*
Management tone was slightly positive but notably constrained on LOTIS-5 specifics, repeatedly emphasizing process limits, including "we're completely blinded to the data" (CEO & Director Ameet Mallik) and "we are on track" (CEO & Director Mallik).
*
Versus the prior quarter, the current call carried more restricted-language signals around communications, including "we will remain in a blackout period" (Chief Financial Officer Jose Carmona) and "we haven't been engaging with analyst or investors since April 1" (CEO & Director Mallik).
QUARTER-OVER-QUARTER COMPARISON
*
The central catalyst remained consistent quarter to quarter, with management reiterating LOTIS-5 "top line" timing in Q2 2026 and positioning it as a key step toward earlier-line expansion, while the current call tightened the near-term message to "before the end of June" (CEO & Director Ameet Mallik).
*
Commercial discussion shifted from Q4’s emphasis on an "unusually low Q3" and "strong" Q4 to Q1’s focus on variability and caution: "it's too soon to call a change in trend" (CEO & Director Mallik).
*
Financial emphasis in Q1 added a structural mix/expense point not highlighted in Q4 prepared remarks: "Cost of product sales increased... [due to] a shift in the allocation of certain personnel costs" (Chief Financial Officer Jose Carmona).
*
Analyst focus was consistent around LOTIS-5 mechanics and disclosures, while the current quarter featured additional scrutiny on the operational process (database lock/unblinding) and potential data components (OS/maturity).
RISKS AND CONCERNS
*
Management flagged disclosure and access risk around the ongoing blinded study process: "we are currently still blinded to the data" (CEO & Director Ameet Mallik).
*
Management highlighted communications constraints tied to the trial status: "we will remain in a blackout period" and "we may need to cancel our participation in any conferences" (Chief Financial Officer Jose Carmona).
*
Analysts pressed on trial execution/interpretation risks, including IDMC visibility and censoring/dropout dynamics; management response was limited: "I can't comment further" (CEO & Director Mallik).
FINAL TAKEAWAY
Management emphasized steady ZYNLONTA demand with quarter-to-quarter ordering variability, disciplined spending, and multiple 2026 catalysts led by LOTIS-5 top-line data expected by the end of June, followed by a potential sBLA submission by year-end if results are positive. Executives also underscored a constrained communications window tied to remaining blinded, while reiterating a longer-term expansion plan that includes LOTIS-7 and indolent lymphoma IITs, with the stated ambition for $600 million to $1 billion in U.S. peak annual revenues assuming compendia listing and regulatory approval.
Read the full Earnings Call Transcript [https://seekingalpha.com/symbol/adct/earnings/transcripts]
MORE ON ADC THERAPEUTICS
* ADC Therapeutics SA (ADCT) Q1 2026 Earnings Call Transcript [https://seekingalpha.com/article/4897999-adc-therapeutics-sa-adct-q1-2026-earnings-call-transcript]
* ADC Therapeutics SA (ADCT) Discusses ZYNLONTA Strategy, Clinical Progress, and Sales Growth Outlook Transcript [https://seekingalpha.com/article/4886042-adc-therapeutics-sa-adct-discusses-zynlonta-strategy-clinical-progress-and-sales-growth]
* ADC Therapeutics SA 2025 Q4 - Results - Earnings Call Presentation [https://seekingalpha.com/article/4880944-adc-therapeutics-sa-2025-q4-results-earnings-call-presentation]
* ADC Therapeutics Non-GAAP EPS of -$0.13, revenue of $20.85M beats by $0.86M [https://seekingalpha.com/news/4584616-adc-therapeutics-non-gaap-eps-of-0_13-revenue-of-20_85m-beats-by-0_86m]
* ADC Therapeutics outlines $600M–$1B peak revenue target for ZYNLONTA as LOTIS-5 and LOTIS-7 advance [https://seekingalpha.com/news/4562747-adc-therapeutics-outlines-600m-1b-peak-revenue-target-for-zynlonta-as-lotisminus-5-and]
- ADC Therapeutics Q1 Earnings Call Highlights
May 4, 2026
ADC Therapeutics logo
Key Points
ADC reported Q1 2026 net product revenue for ZYNLONTA of $20.0 million (up from $17.4M a year ago), which management said mainly reflects quarter-to-quarter ordering variability with underlying demand broadly stable. The company expects top-line results from the Phase 3 LOTIS-5 trial before the end of June while remaining blinded; the release should include PFS, hazard ratio, key secondary endpoints and safety, and ADC plans an sBLA submission by year-end 2026 if positive but does not expect a 2026 revenue impact from the readout. Non-GAAP adjusted operating expenses fell to $42.9 million (down 13% YoY), GAAP net loss narrowed to $33.0 million, and the company ended the quarter with $231 million in cash, which management says supports a runway at least into 2028. Interested in ADC Therapeutics SA? Here are five stocks we like better.
ADC Therapeutics (NYSE:ADCT) reported first-quarter 2026 net product revenue growth for its lymphoma therapy ZYNLONTA and reiterated expectations for multiple upcoming clinical milestones, led by a near-term top-line readout from its Phase 3 LOTIS-5 trial.
ZYNLONTA revenue rises to $20 million as company points to ordering variability
Chief Executive Officer Ameet Mallik said the company’s commercial focus remains on “execution” and maintaining ZYNLONTA as a “differentiated treatment option for third-line plus DLBCL patients.” First-quarter 2026 net product revenues were $20.0 million, compared with $17.4 million in the prior-year quarter.
→ Roblox Stock Slides to New Low as Safety Changes Weigh on Outlook
Mallik attributed the increase primarily to “normal quarter-to-quarter variability in customer ordering,” adding that “underlying demand [is] broadly stable.” During the Q&A session, management also emphasized caution about interpreting a single quarter as a trend. Addressing the quarterly cadence, the company referenced prior quarter variability, including a lower third quarter and stronger fourth quarter in 2025, and said it was “too soon to call a change in trend.”
Mallik said ADC Therapeutics believes “the relative stability we’ve seen in net product revenues over multiple quarters demonstrates that ZYNLONTA has a clear place in this market,” while describing expansion into earlier lines of therapy and indolent lymphomas as future growth opportunities.
LOTIS-5 top-line data expected by end of June; company says it remains blinded
→ The Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It Launches
Management highlighted LOTIS-5, a Phase 3 confirmatory trial evaluating ZYNLONTA plus rituximab, as the next major catalyst. Mallik said the company expects to share top-line data in the second quarter and “before the end of June,” while noting the team is “currently still blinded to the data.”
Story Continues
During Q&A, when asked about database lock timing and the trial’s event count, the company reiterated that it remains blinded and said it would disclose top-line results after the database is locked and statistical analysis is completed. Management declined to comment on the precise timing of reaching the event target, but said it remains on track to report results in the quarter.
→ 2 Stocks to Watch as the Quantum Space Gets More Crowded
Executives also discussed the scope of the upcoming top-line disclosure. In response to questions from analysts, management said the release is expected to include primary endpoint results such as median progression-free survival (PFS) and hazard ratio, plus information on key secondary endpoints and “top-line safety data.” The company added that more detailed analyses are expected later in the year in connection with a medical meeting or publication.
On overall survival (OS), management said it plans to provide the OS information available at the time of top-line disclosure, whether “mature” or “a trend,” along with other key secondary endpoints including response rate and duration of response. The company did not provide an estimate for OS event maturity.
Management also addressed questions about earlier site-level interventions related to dropout and censoring. The company said the most recent Independent Data Monitoring Committee (IDMC) review was “from a safety standpoint” last fall and that the recommendation was to continue the study as planned; it did not indicate additional IDMC looks since then.
Regulatory and Compendia pathway outlined; company does not expect 2026 revenue impact from LOTIS-5
Chief Financial Officer Jose Carmona said that, assuming positive LOTIS-5 results, ADC Therapeutics plans to submit a supplemental Biologics License Application (sBLA) to the FDA by year-end 2026. Carmona also said full LOTIS-5 results are anticipated by year-end, with potential publication and Compendia inclusion in the first half of 2027 and confirmatory approval after that.
In response to an analyst question about potential near-term prescribing effects, management said it does not expect a revenue impact in 2026 from the LOTIS-5 readout. The company said it expects 2026 to be “largely in line with what the previous years are,” and indicated it expects an increased revenue trajectory beginning next year, with promotion tied to formal approval timing.
The company also noted it entered a blackout/quiet period related to the upcoming LOTIS-5 data release. Management said it has not been engaging with analysts or investors since April 1 other than the earnings process and may need to cancel conference participation and investor meetings until data are disclosed.
Other clinical updates: LOTIS-7 enrollment expected to complete in Q2; indolent lymphoma data later
Beyond LOTIS-5, management provided updates across the ZYNLONTA development program:
LOTIS-7: Mallik said the company expects to complete enrollment of approximately 100 patients at the selected dose level of ZYNLONTA plus ofatumumab in the second quarter of 2026. Full data are anticipated by year-end, with Carmona stating the next update is planned “at a medical meeting by the end of 2026.” Assuming positive results, the company plans to pursue Compendia inclusion and assess a regulatory strategy. Indolent lymphoma investigator-initiated trials (IITs): Management said additional data from multicenter IITs are expected to be shared at medical conferences between the end of 2026 and mid-2027. The trials include ZYNLONTA plus rituximab in relapsed or refractory follicular lymphoma and ZYNLONTA monotherapy in relapsed or refractory marginal zone lymphoma. The company said it plans to assess regulatory and Compendia strategies once sufficient data are available.
Expenses decline year over year; cash balance of $231 million supports runway into 2028
Carmona reported total operating expenses of $46.1 million for the first quarter, with non-GAAP adjusted operating expenses of $42.9 million. Management said adjusted operating expenses were down 13% year over year, “primarily driven by lower R&D expenses.”
On the bottom line, ADC Therapeutics posted a GAAP net loss of $33.0 million, or $0.21 per basic and diluted share, compared with a net loss of $38.6 million, or $0.36 per share, in the first quarter of 2025. On a non-GAAP basis, adjusted net loss was $19.7 million versus $24.0 million a year earlier. Carmona attributed the lower losses primarily to reduced R&D spending, while noting per-share comparisons were also affected by a higher weighted average share count.
Cost of product sales increased by $1.6 million year over year to $3.6 million, which Carmona said reflected a shift in allocation of certain personnel costs from research and development to commercial manufacturing activities. In Q&A, Carmona said the reallocation is expected to continue in subsequent quarters, adding that cost of goods would increase due to the fixed costs now being allocated there.
ADC Therapeutics ended the quarter with $231 million in cash and cash equivalents, down from $261.3 million as of Dec. 31, 2025. Both Mallik and Carmona said the cash position supports an expected runway “at least into 2028.”
Looking ahead, Mallik said the company expects multiple “value-creating catalysts” beginning with the LOTIS-5 readout, and reiterated confidence in the potential for longer-term growth starting in 2027, contingent on clinical outcomes and subsequent regulatory and Compendia steps.
About ADC Therapeutics (NYSE:ADCT)
ADC Therapeutics SA is a clinical-stage biopharmaceutical company focused on the discovery and development of highly targeted antibody-drug conjugates (ADCs) designed to treat hematological malignancies such as non-Hodgkin lymphoma and acute myeloid leukemia. By marrying the specificity of monoclonal antibodies with potent cytotoxic payloads, the company aims to maximize tumor cell eradication while limiting off-target toxicity.
At the core of ADC Therapeutics' portfolio is loncastuximab tesirine-lpyl, a CD19-directed ADC that received accelerated approval from the U.S.
The article "ADC Therapeutics Q1 Earnings Call Highlights" was originally published by MarketBeat.
View Comments
- ADC Therapeutics SA (ADCT) Q1 2026 Earnings Call Transcript
May 4, 2026 · seekingalpha.com
ADC Therapeutics SA (ADCT) Q1 2026 Earnings Call Transcript
- ADC Therapeutics SA (ADCT) Reports Q1 Loss, Beats Revenue Estimates
May 4, 2026 · zacks.com
ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.36 per share a year ago.
- ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates
May 4, 2026 · prnewswire.com
LOTIS-5 Phase 3 topline data expected in second quarter 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year end First quarter 2026 net product revenue of $20.0 million Cash and cash equivalents of $231.0 million as of March 31, 2026, with an expected cash runway at least into 2028 Company to host conference call today at 8:30 a.m. EDT LAUSANNE, Switzerland, May 4, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results for the first quarter ended March 31, 2026, and provided recent operational updates.
- ADC THERAPEUTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES OPERATIONAL UPDATES
May 4, 2026
LOTIS-5 PHASE 3 TOPLINE DATA EXPECTED IN SECOND QUARTER 2026, WITH FULL DATA FOR LOTIS-5 AND LOTIS-7 ANTICIPATED BY YEAR END FIRST QUARTER 2026 NET PRODUCT REVENUE OF $20.0 MILLION CASH AND CASH EQUIVALENTS OF $231.0 MILLION AS OF MARCH 31, 2026, WITH AN EXPECTED CASH RUNWAY AT LEAST INTO 2028 COMPANY TO HOST CONFERENCE CALL TODAY AT 8:30 A.M. EDT LAUSANNE, SWITZERLAND, MAY 4, 2026 /PRNEWSWIRE/ -- ADC THERAPEUTICS SA (NYSE: ADCT), A COMMERCIAL-STAGE GLOBAL LEADER AND PIONEER IN THE FIELD OF ANTIBODY DRUG CONJUGATES (ADCS), TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026, AND PROVIDED RECENT OPERATIONAL UPDATES.
- Here are the major earnings before the open Monday
May 3, 2026
Major earnings expected before the bell on Monday include:
* Norwegian Cruise Line Holdings Ltd. (NCLH [https://seekingalpha.com/symbol/NCLH])
* Tyson Foods (TSN [https://seekingalpha.com/symbol/TSN])
* Axsome Therapeutics (AXSM [https://seekingalpha.com/symbol/AXSM])
Other earnings slated for release before Monday's open include:
* ADCT [https://seekingalpha.com/symbol/ADCT], CCOI [https://seekingalpha.com/symbol/CCOI], CNA [https://seekingalpha.com/symbol/CNA], HESM [https://seekingalpha.com/symbol/HESM], KRYS [https://seekingalpha.com/symbol/KRYS], L [https://seekingalpha.com/symbol/L], MZTI [https://seekingalpha.com/symbol/MZTI], NSPR [https://seekingalpha.com/symbol/NSPR], NSSC [https://seekingalpha.com/symbol/NSSC], PNW [https://seekingalpha.com/symbol/PNW], RLJ [https://seekingalpha.com/symbol/RLJ], TWST [https://seekingalpha.com/symbol/TWST]
* For Seeking Alpha's full earnings season calendar, click here [https://seekingalpha.com/earnings/earnings-calendar].
- Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year?
May 1, 2026 · zacks.com
Here is how ADC Therapeutics SA (ADCT) and Bioventus (BVS) have performed compared to their sector so far this year.
